Prostate Cancer, Hereditary, X-Linked 2

Watchlist

(log in to enable)

Retrieved

2019-09-22

Source

Omim

Trials

—

Genes

RNASEL, HOXB13, ELAC2, MSR1, CHEK2, BRCA2, BRCA1, CDKN1B, MSMB, SRD5A2, CDH1, EPHB2, NBN, TTC28, LARP4B, KDM2A, BCL2L11, TSHZ1, HAUS6, DENND4B, ADGRG1, MBD2, BCAS1, PPFIBP2, TCF7L2, HNF1B, TCF4, B3GAT1, MAD1L1, UHRF1BP1, COL23A1, RN7SKP114, RNU6-491P, RNU6-148P, THEG5, MEIS1-AS3, OACYLP, DUBR, RASSF3, CDCA7, RNF43, MOB2, ATAT1, SUGCT, RFX7, PKNOX2, FBRSL1, KNL1, RNLS, EMSY, RNU6-456P, DOCK2, PAX9, MYO9B, MMP14, POU2F2, MBNL1, MAP2K1, ITGB8, INCENP, CHD3, HLA-DOA, DNMT3B, MECOM, CASP8, BCL2, ATM, ARHGAP6, TOR1A, KLK3, PCAP, CBX4, HPCX, AMACR, KLF6, AR, HPC3, CYP17A1, MYC, NPEPPS, PROS1, PSAT1, PLAG1, GSTK1, CYP19A1, RGS8, BRIP1, SLCO6A1, MIR888, ARL11, CYP1B1, CYP1A1, RGSL1, SULT1A1, PALB2, ERG, RASA1, PTEN, TP53, VDR, SPOP, PPM1D, PPP2R2A, PON1, PKHD1, LZTS1, MLH1, LGALS8, KLK2, RASA2, PINX1, GSTT1, PDSS2, GSTP1, GSTM1, CT55

Drugs

Mitoxantrone ( NOVANTRONE )

Interested in hearing about new therapies?

For a general discussion of hereditary prostate cancer, see 176807.

Mapping

Gudmundsson et al. (2008) conducted a genomewide single-nucleotide polymorphism (SNP) association study on prostate cancer on over 23,000 Icelanders, followed by a replication study including over 15,500 individuals from Europe and the United States. Two newly identified variants were shown to be associated with prostate cancer: rs5945572 on Xp11.22, and rs721048 on 2p15 (HPC12; 611868). The A allele of rs5945572 showed the strongest association of markers on the X chromosome in analysis of the Icelandic samples (allele-specific OR = 1.21, P = 3.36 x 10(-4)). Combining results from the Icelandic group with those from 7 other prostate cancer study groups of European descent resulted in achievement of genomewide significance for rs5945572: OR = 1.23, P = 3.95 x 10(-13). The rs5945572 SNP is located on Xp11.22, with the closest genes being NUDT10 (300527) and NUDT11 (300528) on Xp11.23. The A allele correlated with a population-attributable risk (PAR) of approximately 7% in individuals of European descent.

Eeles et al. (2008) conducted a genomewide association study (GWAS) using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at or before the age of 60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (less than 0.5 ng/ml). Eeles et al. (2008) analyzed these samples for 541,129 SNPs using the Illumina Infinium platform. Initial putative associations were confirmed using a further 3,268 cases and 3,366 controls. Eeles et al. (2008) identified association of a SNP on chromosome Xp, rs5945619 (P = 1.5 x 10(-9)), between NUDT10 and NUDT11 (about 2 kb upstream of the latter).